Document Type

Journal Article

Keywords

ABC transporter, ABC transporter B5, antineoplastic agent, biological marker, CD146 antigen, melan A, recombinant alpha2b interferon, transcription factor PAX3, transcription factor PAX3d, transforming growth factor beta2, unclassified drug, adult, aged, article, blood sampling, cancer chemotherapy, cancer patient, cancer prognosis, cancer radiotherapy, cancer surgery, cancer therapy, circulating tumor cell, controlled study, cutaneous melanoma, diagnostic test accuracy study, disease severity, female, histopathology, human, human cell, major clinical study, male, melanoma, melanoma cell, metastatic melanoma, multicenter study, phenotype, predictive value, priority journal, protein expression, protein localization, radiofrequency ablation, real time polymerase chain reaction, reverse transcription polymerase chain reaction, sensitivity and specificity, skin surgery, treatment outcome, tumor growth, tumor recurrence, Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplastic Cells, Circulating, Phenotype, Real-Time Polymerase Chain Reaction, Skin Neoplasms, Treatment Outcome, Tumor Burden, Tumor Markers, Biological, Young Adult

Publisher

Wiley

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences

RAS ID

14341

Comments

This is the pre-peer reviewed version of the following article: Reid, A. L., Millward, M., Pearce, R. , Lee, M., Frank, M., Ireland, A., Monshizadeh, L., Rai, T. , Heenan, P., Medic, S. , Kumarasinghe, P., & Ziman, M. R. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. British Journal of Dermatology, 168(1), 85-92., which has been published in final form at https://doi.org/10.1111/bjd.12057. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Abstract

Background Multimarker quantitative real-time polymerase chain reaction (qRT-PCR) represents an effective method for detecting circulating tumour cells in the peripheral blood of patients with melanoma. Objectives To investigate whether the phenotype of circulating melanoma cells represents a useful indicator of disease stage, recurrence and treatment efficacy. Methods Peripheral blood was collected from 230 patients with melanoma and 152 healthy controls over a period of 3 years and 9 months. Clinical data and blood samples were collected from patients with primary melanoma (early stages, 0-II, n = 154) and metastatic melanoma (late stages, III-IV, n = 76). Each specimen was examined by qRT-PCR analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM. Results In total, 212 of the patients with melanoma (92%) expressed markers in their peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and were identified as statistically significant among patients who experienced disease recurrence within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients with recurrence (P = 0·001 and P = 0·031, respectively). For patients administered nonsurgical treatments, MCAM expression correlated with poor treatment outcome. Conclusions Circulating tumour cells were detectable at all stages of disease and long after surgical treatment, even when patients were considered disease free. Specifically, expression of ABCB5 and MLANA had significant prognostic value in inferring disease recurrence, while MCAM expression was associated with poor patient outcome after treatment, confirming multimarker qRT-PCR as a potential technique for monitoring disease status. See also the Commentary by Sullivan

Access Rights

free_to_read

Download

Share

 
COinS
 

Link to publisher version (DOI)

10.1111/bjd.12057